Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (687)	5/29/1998 8:10:00 AM
From: PawPr	Read Replies (1) \| Respond to of 965

If the two treatments are equally effective, certainly ProSorba, which is free of side effects, would be a better choice. The only way to determine which is a better choice is a head to head comparison between the two, which obviously has not been done. Both Avakine and the ProSorba column have great potential for treatment of other inflammatory and autoimmune disorders, and given the lack of coverage of CYPB, it could be one of those sleeper stocks that turns into a grand slam home run. ( By the way, check out Vickers Insider Trading Reports. There's been a huge amount of insider and institutional buying in CYPB, more than I've ever seen in any other stock ).